Biopharma transaction volumes remained resilient last year despite lesser dealmaking activity across the industry. That deal volume is expected to continue in 2024 as patents expire between 2025-2030, putting large pharmaceutical companies’ revenues at risk and positioning them to fill their pipelines by acquiring late- or commercial-stage biotechs. We take a deeper look at this trend.
To read the entire story, you must be logged in.
Please log in now or register with us.
